Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 97 entries
Sorted by: Best Match Show Resources per page
Selection in the anomalous Saffman-Taylor fingers induced by a bubble.

Physical review. A, General physics

Combescot R, Dombre T.
PMID: 9901655
Phys Rev A Gen Phys. 1989 Apr 01;39(7):3525-3535. doi: 10.1103/physreva.39.3525.

No abstract available.

Cite
Combescot R, Dombre T. Selection in the anomalous Saffman-Taylor fingers induced by a bubble. Phys Rev A Gen Phys. 1989;39(7):3525-3535doi: 10.1103/physreva.39.3525.
Combescot, R., & Dombre, T. (1989). Selection in the anomalous Saffman-Taylor fingers induced by a bubble. Physical review. A, General physics, 39(7), 3525-3535. https://doi.org/10.1103/physreva.39.3525
Combescot, and Dombre. "Selection in the anomalous Saffman-Taylor fingers induced by a bubble." Physical review. A, General physics vol. 39,7 (1989): 3525-3535. doi: https://doi.org/10.1103/physreva.39.3525
Combescot R, Dombre T. Selection in the anomalous Saffman-Taylor fingers induced by a bubble. Phys Rev A Gen Phys. 1989 Apr 01;39(7):3525-3535. doi: 10.1103/physreva.39.3525. PMID: 9901655.
Copy Download .nbib Format: NLM
Two-particle correlations at small relative momenta for 40Ar-induced reactions on 197Au at E/A=60 MeV.

Physical review. C, Nuclear physics

Ardouin D, Bizard G, Boal DH, Delagrange H, Doubre H, Friedman WA, Gelbke CK, Grégoire C, Kyanowski A, Lefèbvres F, Lynch WG, Maier M, Mittig W, Péghaire A, Péter J, Pochodzalla J, Québert J, Saint-Laurent F, Tamain B, Viyogi YP, Zwieglinski B.
PMID: 9953958
Phys Rev C Nucl Phys. 1987 May;35(5):1695-1719. doi: 10.1103/physrevc.35.1695.

No abstract available.

Cite
Ardouin D, Bizard G, Boal DH, et al. Two-particle correlations at small relative momenta for 40Ar-induced reactions on 197Au at E/A=60 MeV. Phys Rev C Nucl Phys. 1987;35(5):1695-1719doi: 10.1103/physrevc.35.1695.
Ardouin, D., Bizard, G., Boal, D. H., Delagrange, H., Doubre, H., Friedman, W. A., Gelbke, C. K., Grégoire, C., Kyanowski, A., Lefèbvres, F., Lynch, W. G., Maier, M., Mittig, W., Péghaire, A., Péter, J., Pochodzalla, J., Québert, J., Saint-Laurent, F., Tamain, B., Viyogi, Y. P., & Zwieglinski, B. (1987). Two-particle correlations at small relative momenta for 40Ar-induced reactions on 197Au at E/A=60 MeV. Physical review. C, Nuclear physics, 35(5), 1695-1719. https://doi.org/10.1103/physrevc.35.1695
Ardouin, et al. "Two-particle correlations at small relative momenta for 40Ar-induced reactions on 197Au at E/A=60 MeV." Physical review. C, Nuclear physics vol. 35,5 (1987): 1695-1719. doi: https://doi.org/10.1103/physrevc.35.1695
Ardouin D, Bizard G, Boal DH, Delagrange H, Doubre H, Friedman WA, Gelbke CK, Grégoire C, Kyanowski A, Lefèbvres F, Lynch WG, Maier M, Mittig W, Péghaire A, Péter J, Pochodzalla J, Québert J, Saint-Laurent F, Tamain B, Viyogi YP, Zwieglinski B. Two-particle correlations at small relative momenta for 40Ar-induced reactions on 197Au at E/A=60 MeV. Phys Rev C Nucl Phys. 1987 May;35(5):1695-1719. doi: 10.1103/physrevc.35.1695. PMID: 9953958.
Copy Download .nbib Format: NLM
Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.

Blood

Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H.
PMID: 34995344
Blood. 2022 Jan 07; doi: 10.1182/blood.2021013404. Epub 2022 Jan 07.

Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Post-remission maintenance therapy that prolongs MRD negativity or converts MRD positive (MRD+) patients to MRD...

Cite
Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. Blood. 2022;doi: 10.1182/blood.2021013404.
Roboz, G. J., Ravandi, F., Wei, A. H., Dombret, H., Thol, F., Voso, M. T., Schuh, A. C., Porkka, K., La Torre, I., Skikne, B. S., Zhong, J., Beach, C. L., Risueño, A., Lopes de Menezes, D., Ossenkoppele, G. J., & Döhner, H. (2022). Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. Blood, . https://doi.org/10.1182/blood.2021013404
Roboz, Gail J, et al. "Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status." Blood vol. (2022). doi: https://doi.org/10.1182/blood.2021013404
Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H. Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. Blood. 2022 Jan 07; doi: 10.1182/blood.2021013404. Epub 2022 Jan 07. PMID: 34995344.
Copy Download .nbib Format: NLM
Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis.

Pulmonology

Combret Y, Prieur G, Boujibar F, Gravier FE, Smondack P, Le Roux P, Bonnevie T, Medrinal C, Reychler G.
PMID: 34844914
Pulmonology. 2021 Nov 26; doi: 10.1016/j.pulmoe.2021.10.005. Epub 2021 Nov 26.

No abstract available.

Cite
Combret Y, Prieur G, Boujibar F, et al. Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis. Pulmonology. 2021;doi: 10.1016/j.pulmoe.2021.10.005.
Combret, Y., Prieur, G., Boujibar, F., Gravier, F. E., Smondack, P., Le Roux, P., Bonnevie, T., Medrinal, C., & Reychler, G. (2021). Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis. Pulmonology, . https://doi.org/10.1016/j.pulmoe.2021.10.005
Combret, Yann, et al. "Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis." Pulmonology vol. (2021). doi: https://doi.org/10.1016/j.pulmoe.2021.10.005
Combret Y, Prieur G, Boujibar F, Gravier FE, Smondack P, Le Roux P, Bonnevie T, Medrinal C, Reychler G. Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis. Pulmonology. 2021 Nov 26; doi: 10.1016/j.pulmoe.2021.10.005. Epub 2021 Nov 26. PMID: 34844914.
Copy Download .nbib Format: NLM
Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open

Dinh A, Duran C, Ropers J, Bouchand F, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Mellon G, Calin R, Makhloufi S, de Lastours V, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Guillemot D, Renaud B, Claessens YE, Labarère J, Aegerter P, Bedos JP, Crémieux AC.
PMID: 34652445
JAMA Netw Open. 2021 Oct 01;4(10):e2129566. doi: 10.1001/jamanetworkopen.2021.29566.

IMPORTANCE: Failure of treatment is the most serious complication in community-acquired pneumonia (CAP).OBJECTIVE: To assess the potential risk factors for treatment failure in clinically stable patients with CAP.DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis assesses data from a randomized...

Cite
Dinh A, Duran C, Ropers J, et al. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021;4(10):e2129566doi: 10.1001/jamanetworkopen.2021.29566.
Dinh, A., Duran, C., Ropers, J., Bouchand, F., Davido, B., Deconinck, L., Matt, M., Senard, O., Lagrange, A., Mellon, G., Calin, R., Makhloufi, S., de Lastours, V., Mathieu, E., Kahn, J. E., Rouveix, E., Grenet, J., Dumoulin, J., Chinet, T., Pépin, M., Delcey, V., Diamantis, S., Benhamou, D., Vitrat, V., Dombret, M. C., Guillemot, D., Renaud, B., Claessens, Y. E., Labarère, J., Aegerter, P., Bedos, J. P., Crémieux, A. C. (2021). Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open, 4(10), e2129566. https://doi.org/10.1001/jamanetworkopen.2021.29566
Dinh, Aurélien, et al. "Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial." JAMA network open vol. 4,10 (2021): e2129566. doi: https://doi.org/10.1001/jamanetworkopen.2021.29566
Dinh A, Duran C, Ropers J, Bouchand F, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Mellon G, Calin R, Makhloufi S, de Lastours V, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Guillemot D, Renaud B, Claessens YE, Labarère J, Aegerter P, Bedos JP, Crémieux AC. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021 Oct 01;4(10):e2129566. doi: 10.1001/jamanetworkopen.2021.29566. PMID: 34652445; PMCID: PMC8520128.
Copy Download .nbib Format: NLM
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.

Haematologica

Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH.
PMID: 34551506
Haematologica. 2021 Dec 01;106(12):3240-3244. doi: 10.3324/haematol.2021.279174.

No abstract available.

Cite
Roboz GJ, Döhner H, Pocock C, et al. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica. 2021;106(12):3240-3244doi: 10.3324/haematol.2021.279174.
Roboz, G. J., Döhner, H., Pocock, C., Dombret, H., Ravandi, F., Jang, J. H., Selleslag, D., Mayer, J., Martens, U. M., Liesveld, J., Bernal, T., Wang, M. C., Yu, P., Shi, L., Guo, S., La Torre, I., Skikne, B., Dong, Q., Braverman, J., Nehme, S. A., Beach, C. L., & Wei, A. H. (2021). Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica, 106(12), 3240-3244. https://doi.org/10.3324/haematol.2021.279174
Roboz, Gail J, et al. "Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial." Haematologica vol. 106,12 (2021): 3240-3244. doi: https://doi.org/10.3324/haematol.2021.279174
Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica. 2021 Dec 01;106(12):3240-3244. doi: 10.3324/haematol.2021.279174. PMID: 34551506; PMCID: PMC8634169.
Copy Download .nbib Format: NLM
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Respiratory medicine

Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H.
PMID: 34506761
Lancet Respir Med. 2021 Sep 07; doi: 10.1016/S2213-2600(21)00354-4. Epub 2021 Sep 07.

BACKGROUND: The use of cyclophosphamide in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) is unknown. Our study was designed to evaluate the efficacy and safety of four cyclophosphamide pulses in addition to high-dose methylprednisolone in this population.METHODS:...

Cite
Naccache JM, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;doi: 10.1016/S2213-2600(21)00354-4.
Naccache, J. M., Jouneau, S., Didier, M., Borie, R., Cachanado, M., Bourdin, A., Reynaud-Gaubert, M., Bonniaud, P., Israël-Biet, D., Prévot, G., Hirschi, S., Lebargy, F., Marchand-Adam, S., Bautin, N., Traclet, J., Gomez, E., Leroy, S., Gagnadoux, F., Rivière, F., Bergot, E., Gondouin, A., Blanchard, E., Parrot, A., Blanc, F. X., Chabrol, A., Dominique, S., Gibelin, A., Tazi, A., Berard, L., Brillet, P. Y., Debray, M. P., Rousseau, A., Kerjouan, M., Freynet, O., Dombret, M. C., Gamez, A. S., Nieves, A., Beltramo, G., Pastré, J., Le Borgne-Krams, A., Dégot, T., Launois, C., Plantier, L., Wémeau-Stervinou, L., Cadranel, J., Chenivesse, C., Valeyre, D., Crestani, B., Cottin, V., Simon, T., Nunes, H. (2021). Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine, . https://doi.org/10.1016/S2213-2600(21)00354-4
Naccache, Jean-Marc, et al. "Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet. Respiratory medicine vol. (2021). doi: https://doi.org/10.1016/S2213-2600(21)00354-4
Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Sep 07; doi: 10.1016/S2213-2600(21)00354-4. Epub 2021 Sep 07. PMID: 34506761.
Copy Download .nbib Format: NLM
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

Blood

Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N.
PMID: 34410352
Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103.

To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute...

Cite
Itzykson R, Fournier E, Berthon C, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507-519doi: 10.1182/blood.2021011103.
Itzykson, R., Fournier, E., Berthon, C., Röllig, C., Braun, T., Marceau-Renaut, A., Pautas, C., Nibourel, O., Lemasle, E., Micol, J. B., Adès, L., Lebon, D., Malfuson, J. V., Gastaud, L., Goursaud, L., Raffoux, E., Wattebled, K. J., Rousselot, P., Thomas, X., Chantepie, S., Cluzeau, T., Serve, H., Boissel, N., Terré, C., Celli-Lebras, K., Preudhomme, C., Thiede, C., Dombret, H., Gardin, C., & Duployez, N. (2021). Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 138(7), 507-519. https://doi.org/10.1182/blood.2021011103
Itzykson, Raphael, et al. "Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy." Blood vol. 138,7 (2021): 507-519. doi: https://doi.org/10.1182/blood.2021011103
Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103. PMID: 34410352.
Copy Download .nbib Format: NLM
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.

Blood

Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, Braun T, Adès L, Chantepie S, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, Celli-Lebras K, Caillot D, Turlure P, Vey N, Pigneux A, Recher C, Terré C, Gardin C, Itzykson R, Preudhomme C, Dombret H, de Botton S.
PMID: 33881523
Blood. 2021 May 20;137(20):2827-2837. doi: 10.1182/blood.2020010165.

In patients with isocitrate dehydrogenase (IDH)-mutated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic alterations and allogeneic hematopoietic stem cell transplantation (HSCT) are of particular interest with the advent of IDH1/2 mutant inhibitors....

Cite
Duchmann M, Micol JB, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137(20):2827-2837doi: 10.1182/blood.2020010165.
Duchmann, M., Micol, J. B., Duployez, N., Raffoux, E., Thomas, X., Marolleau, J. P., Braun, T., Adès, L., Chantepie, S., Lemasle, E., Berthon, C., Malfuson, J. V., Pautas, C., Lambert, J., Boissel, N., Celli-Lebras, K., Caillot, D., Turlure, P., Vey, N., Pigneux, A., Recher, C., Terré, C., Gardin, C., Itzykson, R., Preudhomme, C., Dombret, H., & de Botton, S. (2021). Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood, 137(20), 2827-2837. https://doi.org/10.1182/blood.2020010165
Duchmann, Matthieu, et al. "Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study." Blood vol. 137,20 (2021): 2827-2837. doi: https://doi.org/10.1182/blood.2020010165
Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, Braun T, Adès L, Chantepie S, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, Celli-Lebras K, Caillot D, Turlure P, Vey N, Pigneux A, Recher C, Terré C, Gardin C, Itzykson R, Preudhomme C, Dombret H, de Botton S. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021 May 20;137(20):2827-2837. doi: 10.1182/blood.2020010165. PMID: 33881523.
Copy Download .nbib Format: NLM
Focal bronchial dilatations after thermoplasty for severe asthma.

ERJ open research

Thibaut de Ménonville C, Debray MP, Alavoine L, Dombret MC, Khalil A, Brillet PY, Aubier M, Taillé C.
PMID: 32963997
ERJ Open Res. 2020 Sep 14;6(3). doi: 10.1183/23120541.00117-2020. eCollection 2020 Jul.

No abstract available.

Cite
Thibaut de Ménonville C, Debray MP, Alavoine L, et al. Focal bronchial dilatations after thermoplasty for severe asthma. ERJ Open Res. 2020;6(3)doi: 10.1183/23120541.00117-2020.
Thibaut de Ménonville, C., Debray, M. P., Alavoine, L., Dombret, M. C., Khalil, A., Brillet, P. Y., Aubier, M., & Taillé, C. (2020). Focal bronchial dilatations after thermoplasty for severe asthma. ERJ open research, 6(3), . https://doi.org/10.1183/23120541.00117-2020
Thibaut de Ménonville, Charlotte, et al. "Focal bronchial dilatations after thermoplasty for severe asthma." ERJ open research vol. 6,3 (2020). doi: https://doi.org/10.1183/23120541.00117-2020
Thibaut de Ménonville C, Debray MP, Alavoine L, Dombret MC, Khalil A, Brillet PY, Aubier M, Taillé C. Focal bronchial dilatations after thermoplasty for severe asthma. ERJ Open Res. 2020 Sep 14;6(3). doi: 10.1183/23120541.00117-2020. eCollection 2020 Jul. PMID: 32963997; PMCID: PMC7487351.
Copy Download .nbib Format: NLM
Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial.

BMJ open respiratory research

Medrinal C, Prieur G, Debeaumont D, Robledo Quesada A, Combret Y, Quieffin J, Contal O, Lamia B.
PMID: 27110364
BMJ Open Respir Res. 2016 Apr 12;3(1):e000130. doi: 10.1136/bmjresp-2016-000130. eCollection 2016.

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) has systemic repercussions that can lead to peripheral muscle dysfunction. Muscle atrophy reduces aerobic capacity, greatly limiting activities of daily living and quality of life. Pulmonary rehabilitation is the gold standard treatment for...

Cite
Medrinal C, Prieur G, Debeaumont D, et al. Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial. BMJ Open Respir Res. 2016;3(1):e000130doi: 10.1136/bmjresp-2016-000130.
Medrinal, C., Prieur, G., Debeaumont, D., Robledo Quesada, A., Combret, Y., Quieffin, J., Contal, O., & Lamia, B. (2016). Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial. BMJ open respiratory research, 3(1), e000130. https://doi.org/10.1136/bmjresp-2016-000130
Medrinal, Clément, et al. "Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial." BMJ open respiratory research vol. 3,1 (2016): e000130. doi: https://doi.org/10.1136/bmjresp-2016-000130
Medrinal C, Prieur G, Debeaumont D, Robledo Quesada A, Combret Y, Quieffin J, Contal O, Lamia B. Comparison of oxygen uptake during cycle ergometry with and without functional electrical stimulation in patients with COPD: protocol for a randomised, single-blind, placebo-controlled, cross-over trial. BMJ Open Respir Res. 2016 Apr 12;3(1):e000130. doi: 10.1136/bmjresp-2016-000130. eCollection 2016. PMID: 27110364; PMCID: PMC4838753.
Copy Download .nbib Format: NLM
Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).

Biomedicines

Djamai H, Berrou J, Dupont M, Coudé MM, Delord M, Clappier E, Marceau-Renaut A, Kaci A, Raffoux E, Itzykson R, Berthier C, Wu HC, Hleihel R, Bazarbachi A, de Thé H, Baruchel A, Gardin C, Dombret H, Braun T.
PMID: 34829934
Biomedicines. 2021 Nov 17;9(11). doi: 10.3390/biomedicines9111704.

BET inhibitors (BETi) including OTX015 (MK-8628) and JQ1 demonstrated antileukemic activity including

Cite
Djamai H, Berrou J, Dupont M, et al. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines. 2021;9(11)doi: 10.3390/biomedicines9111704.
Djamai, H., Berrou, J., Dupont, M., Coudé, M. M., Delord, M., Clappier, E., Marceau-Renaut, A., Kaci, A., Raffoux, E., Itzykson, R., Berthier, C., Wu, H. C., Hleihel, R., Bazarbachi, A., de Thé, H., Baruchel, A., Gardin, C., Dombret, H., & Braun, T. (2021). Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines, 9(11), . https://doi.org/10.3390/biomedicines9111704
Djamai, Hanane, et al. "Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)." Biomedicines vol. 9,11 (2021). doi: https://doi.org/10.3390/biomedicines9111704
Djamai H, Berrou J, Dupont M, Coudé MM, Delord M, Clappier E, Marceau-Renaut A, Kaci A, Raffoux E, Itzykson R, Berthier C, Wu HC, Hleihel R, Bazarbachi A, de Thé H, Baruchel A, Gardin C, Dombret H, Braun T. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines. 2021 Nov 17;9(11). doi: 10.3390/biomedicines9111704. PMID: 34829934; PMCID: PMC8615962.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 97 entries